Search results
Showing 1 to 14 of 14 results for nasal polyps
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (TA1134)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe chronic rhinosinusitis with nasal polyps in adults.
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA678)
NICE is unable to make a recommendation on omalizumab (Xolair) for treating chronic rhinosinusitis with nasal polyps in adults because Novartis Pharmaceuticals did not provide an evidence submission.
Show all sections
Sections for TA678
NICE is unable to make a recommendation on depemokimab (Exdensur) for treating chronic rhinosinusitis with nasal polyps in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1123
NICE is unable to make a recommendation on mepolizumab (Nucala) for treating severe chronic rhinosinusitis with nasal polyps in adults because GSK did not provide an evidence submission.
Show all sections
Sections for TA847
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379
In development Reference number: GID-TA11429 Expected publication date: 09 September 2026
XprESS multi sinus dilation system for treating chronic sinusitis (HTG424)
Evidence-based recommendations on the XprESS multi-sinus dilation system for treating chronic sinusitis after medical treatment has failed.
PROPEL sinus implants for maintaining sinus patency after surgery (MIB253)
NICE has developed a medtech innovation briefing (MIB) on PROPEL sinus implants for maintaining sinus patency after surgery .
Benralizumab for previously treated severe nasal polyps [ID1659]
In development Reference number: GID-TA10818 Expected publication date: TBC
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.
This guideline covers diagnosing and managing drug allergy in all age groups. It aims to make it easier for professionals to tell when someone is having an allergic reaction, by specifying the key signs and patterns to look out for. It also makes recommendations on improving people’s understanding of their drug allergies, and ensuring these are recorded properly in their medical records.
This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.